Palvella Therapeutics, Inc. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
Palvella Therapeutics, Inc. (PVLA) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $1.76 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2019-03-18
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-12-31 was $207.00K, a 55.00% decline year-over-year.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-09-30 was $472.00K, a 79.47% increase year-over-year.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-06-30 was $467.00K, a 34.97% increase year-over-year.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2018-03-31 was $617.00K, a 84.18% increase year-over-year.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2018 was $1.76M, a 25.59% increase from fiscal 2017.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2017 was $1.40M, a 2.57% decline from fiscal 2016.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2016 was $1.44M, a 25646.47% increase from fiscal 2015.
- Palvella Therapeutics, Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2015 was $5.59K, a 99.36% decline from fiscal 2014.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $679.00K derived: sum of 2 quarters · filed 2019-03-18 | $1.15M derived: sum of 3 quarters · filed 2019-03-18 | $1.76M 10-K · filed 2019-03-18 | |
| 2018-09-30 | $472.00K 10-Q · filed 2018-11-07 | $939.00K derived: sum of 2 quarters · filed 2018-11-07 | $1.55M 10-Q · filed 2018-11-07 | $2.02M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2018-06-30 | $467.00K 10-Q · filed 2018-08-09 | $1.08M 10-Q · filed 2018-08-09 | $1.54M derived: sum of 3 quarters · filed 2019-03-18 | $1.81M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2018-03-31 | $617.00K 10-Q · filed 2018-05-10 | $1.08M derived: sum of 2 quarters · filed 2019-03-18 | $1.34M derived: sum of 3 quarters · filed 2019-03-18 | $1.69M derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $723.00K derived: sum of 2 quarters · filed 2019-03-18 | $1.07M derived: sum of 3 quarters · filed 2019-03-18 | $1.40M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $263.00K 10-Q · filed 2018-11-07 | $609.00K derived: sum of 2 quarters · filed 2018-11-07 | $943.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $346.00K 10-Q · filed 2018-08-09 | $680.00K 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | $335.00K 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | $1.44M 10-K · filed 2018-03-15 | $1.44M 10-K · filed 2017-03-30 | |||
| 2015-12-31 | $5.59K 10-K · filed 2017-03-30 | ||||
| 2014-12-31 | $876.62K 10-K · filed 2016-03-23 | ||||
| 2013-12-31 | $3.59M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |